Background: MicroRNAs, as a class of small, well-conserved, non-coding RNAs, are increasing identified as diagnostic biomarkers in many cancers. The dysregulated microRNA-129 (miR-129) is closely related with tumorigenesis and cancer progression. However, their potential role of miR-129 in prostate cancer still remains largely elusive.
Aim: In this study, we aimed to investigate the evidence of miR-129 as prognostic biomarkers for tumor progression and clinical prognosis in prostate cancer patients.
Results: The prostate cancer tissues exhibited a significant reduction in miR-129 expression compared with the paracancerous tissues (P<0.05). The miR-129 expression is negatively correlated with histological grade (P=0.000), high preoperative PSA level (P=0.000), pathological stage (P=0.000), high Gleason score (P=0.000), lymph node metastasis (P=0.002), angiolymphatic invasion (P=0.018), biochemical recurrence (P=0.001). Kaplan-Meier analysis demonstrated that low miR-129 expression level was closely associated with poorer biochemical recurrence (BCR)-free survival. Further analysis indicated that (P=0.000) expression may be and independent prognostic factor for BCR-free survival prostate cancer patients (P=0.000). Overexpression of miR-129 markedly attenuated the prostate cancer cell growth via rescuing the dysregulated cell cycle regulatory protein expression.
Conclusions: Taken together, miR-129 was down-regulated in prostate cancer tissues in prostate cancer patients. It may be considered as a novel independent prognostic biomarker for prostate cancer. Downregulation of Mir-129 plays a critical role in proliferation of prostate cancer.
